Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models

References

• Thiberville SD, Moyen N, Dupuis-Maguiraga L, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013 Sep;99(3):345–370.
   PubMed Web of Science ®Google Scholar
• Fox JM, Diamond MS. Immune-mediated protection and pathogenesis of Chikungunya virus. J Immunol. 2016 Dec 1;197(11):4210–4218.
   PubMed Web of Science ®Google Scholar
• Poh CM, Chan YH, Ng LFP. Role of T cells in Chikungunya virus infection and utilizing their potential in anti-viral immunity. Front Immunol. 2020;11:287.
   Web of Science ®Google Scholar
• Schwameis M, Buchtele N, Wadowski PP, et al. Chikungunya vaccines in development. Hum Vaccin Immunother. 2016 Mar 3;12(3):716–731.
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010 Mar;16(3):334–338.
   PubMed Web of Science ®Google Scholar
• Chang LJ, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014 Dec 6;384(9959):2046–2052.
   PubMed Web of Science ®Google Scholar
• Ramsauer K, Schwameis M, Firbas C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015 May;15(5):519–527.
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus [Research support. Non-U.S. Gov't]. Vaccine. 2013 Aug 12;31(36):3718–3725.
   PubMed Web of Science ®Google Scholar
• Wressnigg N, Hochreiter R, Zoihsl O, et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020 Oct;20(10):1193–1203.
   Web of Science ®Google Scholar
• Gorchakov R, Wang E, Leal G, et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol. 2012 Jun;86(11):6084–6096.
   PubMed Web of Science ®Google Scholar
• Weiss CM, Liu H, Riemersma KK, et al. Engineering a fidelity-variant live-attenuated vaccine for chikungunya virus. NPJ Vaccines. 2020;5:97.
   Web of Science ®Google Scholar
• Meshram CD, Lukash T, Phillips AT, et al. Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo. Virology. 2019 Aug;534:14–24.
   Web of Science ®Google Scholar
• Chu H, Das SC, Fuchs JF, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 2013 Jul 18;31(33):3353–3360.
   Web of Science ®Google Scholar
• Partidos CD, Paykel J, Weger J, et al. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine. 2012 Jun 29;30(31):4638–4643.
   Web of Science ®Google Scholar
• Wang E, Kim DY, Weaver SC, et al. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J Virol. 2011 Sep;85(17):9249–9252.
   PubMed Web of Science ®Google Scholar
• Kim DY, Atasheva S, Foy NJ, et al. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol. 2011 May;85(9):4363–4376.
   PubMed Web of Science ®Google Scholar
• Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine. 2008 Sep 15;26(39):5030–5039.
   PubMed Web of Science ®Google Scholar
• Nasar F, Palacios G, Gorchakov RV, et al. Eilat virus, a unique alphavirus with host range restricted to insects by RNA replication. Proc Natl Acad Sci USA. 2012 Sep 4;109(36):14622–14627.
   Web of Science ®Google Scholar
• Nasar F, Gorchakov RV, Tesh RB, et al. Eilat virus host range restriction is present at multiple levels of the virus life cycle. J Virol. 2015 Jan 15;89(2):1404–1418.
   Web of Science ®Google Scholar
• Erasmus JH, Auguste AJ, Kaelber JT, et al. A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med. 2017 Feb;23(2):192–199.
   Web of Science ®Google Scholar
• Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Lennete ET, Lennete DA, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 7th ed. Washington, DC: American Public Health Association. 1995. p. 189–212.
   Google Scholar
• Wang T, Town T, Alexopoulou L, et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004 Dec;10(12):1366–1373.
   PubMed Web of Science ®Google Scholar
• Xie G, Luo H, Pang L, et al. Dysregulation of Toll-like receptor 7 compromises innate and adaptive T cell responses and host resistance to an attenuated West Nile virus infection in old mice. J Virol. 2016 Feb 1;90(3):1333–1344.
   Web of Science ®Google Scholar
• Welte T, Aronson J, Gong B, et al. Vgamma4+ T cells regulate host immune response to West Nile virus infection. FEMS Immunol Med Microbiol. 2011 Nov;63(2):183–192.
   Google Scholar
• Hallengard D, Lum FM, Kummerer BM, et al. Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014 Nov;88(22):13333–13343.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Lankaraman KM, Laddy DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine. 2008 Sep 19;26(40):5128–5134.
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Needham J, Raychaudhuri S, et al. Utilization of an Eilat virus-based chimera for serological detection of Chikungunya infection. PLoS Negl Trop Dis. 2015;9(10):e0004119.
   Web of Science ®Google Scholar
• Adam A, Woda M, Kounlavouth S, et al. Multiplexed FluoroSpot for the analysis of Dengue virus- and Zika virus-specific and cross-reactive memory B cells. J Immunol. 2018 Dec 15;201(12):3804–3814.
   Web of Science ®Google Scholar
• Nasar F, Erasmus JH, Haddow AD, et al. Eilat virus induces both homologous and heterologous interference. Virology. 2015 Oct;484:51–58.
   Web of Science ®Google Scholar
• Schuchman R, Kilianski A, Piper A, et al. Comparative characterization of the Sindbis virus proteome from mammalian and invertebrate hosts identifies nsP2 as a component of the virion and sorting Nexin 5 as a significant host factor for alphavirus replication. J Virol. 2018 Jul 15;92(14):e00694–18.
   Web of Science ®Google Scholar
• Hogrefe WR. Biomarkers and assessment of vaccine responses. Biomarkers. 2005 Nov;10(Suppl 1):S50–S57.
   PubMed Web of Science ®Google Scholar
• Schwameis M, Roppenser B, Firbas C, et al. Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis. 2016 Sep;16(9):1036–1044.
   Web of Science ®Google Scholar
• Scott RM, Shelton AL, Eckels KH, et al. Human hypersensitivity to a sham vaccine prepared from mosquito-cell culture fluids. J Allergy Clin Immunol. 1984 Dec;74(6):808–811.
   Web of Science ®Google Scholar
• Seymour RL, Adams AP, Leal G, et al. A Rodent model of Chikungunya virus infection in RAG1 -/- mice, with features of persistence, for vaccine safety evaluation. PLoS Negl Trop Dis. 2015 Jun;9(6):e0003800.
   PubMed Web of Science ®Google Scholar
• Hawman DW, Stoermer KA, Montgomery SA, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013 Dec;87(24):13878–13888.
   PubMed Web of Science ®Google Scholar
• Davenport BJ, Bullock C, McCarthy MK, et al. Chikungunya virus evades antiviral CD8(+) T cell responses to establish persistent infection in joint-associated tissues. J Virol. 2020 Apr 16;94(9):e02036–19.
   PubMed Web of Science ®Google Scholar
• Broeckel RM, Haese N, Ando T, et al. Vaccine-induced skewing of T cell responses protects against Chikungunya virus disease. Front Immunol. 2019;10:2563.
   Web of Science ®Google Scholar
• Teo TH, Lum FM, Claser C, et al. A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J Immunol. 2013 Jan 1;190(1):259–269.
   PubMed Web of Science ®Google Scholar
• Chien YH, Meyer C, Bonneville M. Gammadelta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121–155.
   PubMed Web of Science ®Google Scholar
• Roark CL, Simonian PL, Fontenot AP, et al. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 2008 Jun;20(3):353–357.
   PubMed Web of Science ®Google Scholar
• Ferrick DA, King DP, Jackson KA, et al. Intraepithelial gamma delta T lymphocytes: sentinel cells at mucosal barriers. Springer Semin Immunopathol. 2000;22(3):283–296.
   Web of Science ®Google Scholar
• O'Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol. 2009 Mar;39(3):662–666.
   PubMed Web of Science ®Google Scholar
• Collins C, Wolfe J, Roessner K, et al. Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand. J Immunol. 2005 Nov 1;175(9):5656–5665.
   PubMed Web of Science ®Google Scholar
• Ismaili J, Olislagers V, Poupot R, et al. Human gamma delta T cells induce dendritic cell maturation. Clin Immunol. 2002 Jun;103(3 Pt 1):296–302.
   Web of Science ®Google Scholar
• Leslie DS, Vincent MS, Spada FM, et al. CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med. 2002 Dec 16;196(12):1575–1584.
   PubMed Web of Science ®Google Scholar
• Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005 Jul 18;202(2):203–207.
   PubMed Web of Science ®Google Scholar
• Long KM, Ferris MT, Whitmore AC, et al. Gammadelta T cells play a protective role in Chikungunya virus-induced disease. J Virol. 2016 Jan 1;90(1):433–443.
   Web of Science ®Google Scholar
• Erasmus JH, Seymour RL, Kaelber JT, et al. Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono- and multivalent, single-dose protection against Lethal alphavirus challenge. J Virol. 2018 Feb 15;92(4):e01274–17.
   PubMed Web of Science ®Google Scholar